BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | A207607 | MYLAN TECHNOLOGIES INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Indivior Inc. et al v. Mylan Technologies Inc. et al 3 patentsANDA 207607buprenorphine hydrochloride and naloxone hydrochloride | D. Del. | 2015-11-04 | Terminated 2019-09-05 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$4.27
per ea
Lowest NADAC/Unit
$1.95
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00378876893BUPRENORPHINE-NALOXONE 12-3 MG SL FILM | $4.27 | EA | Generic | — | 2026-10-21 |
| 00378876793BUPRENORPHINE-NALOXONE 8-2 MG SL FILM | $1.95 | EA | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.